NEW YORK (360Dx) – Seville, Spain-based Universal Diagnostics said last week that it is participating in a clinical study at a network of hospitals in London to validate its large-scale screening test for detection of early-stage colorectal cancer and adenomas.

The test uses mass spectrometry and a panel of 30 small-molecule metabolomics biomarkers, including lipids and amino acids, to measure metabolites in blood samples that are linked to the presence of colorectal cancer and precancerous cells, or adenomas.